[go: up one dir, main page]

CY1113554T1 - Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870 - Google Patents

Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870

Info

Publication number
CY1113554T1
CY1113554T1 CY20131100064T CY131100064T CY1113554T1 CY 1113554 T1 CY1113554 T1 CY 1113554T1 CY 20131100064 T CY20131100064 T CY 20131100064T CY 131100064 T CY131100064 T CY 131100064T CY 1113554 T1 CY1113554 T1 CY 1113554T1
Authority
CY
Cyprus
Prior art keywords
nmb1870
family
families
domains
trans
Prior art date
Application number
CY20131100064T
Other languages
English (en)
Inventor
Vega Masignani
Maria Scarselli
Rino Rappuoli
Mariagrazia Pizza
Marzia Giuliani
Marcello Federica Di
Daniele Veggi
Laura Ciucchi
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1113554T1 publication Critical patent/CY1113554T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

«ΝΜΒ1870» είναι μια γνωστή πρωτεΐνη επιφανείας σε Neisseria meningitidis εκφρασμένη σε όλες τις οροομάδες. Έχει τρεις διακριτές οικογένειες. Ορός εγειρόμενος έναντι μιας δοθείσας οικογένειας είναι βακτηριοκτόνος εντός της ίδιας οικογένειας, αλλά δεν είναι δραστικός έναντι στελεχών, τα οποία εκφράζουν μία από τις άλλες δύο οικογένειες, δηλαδή ενδο-οικογένειας αλλά όχι δια-οικογένειας εγκάρσια-προστασία. Οι εφευρέτες έχουν βρει ότι η ΝΜΒ1870 μπορεί να διαιρείται σε πεδία και ότι δεν απαιτούνται όλα τα πεδία για αντιγονικότητα. Αντιγονικά πεδία μπορεί να ληφθούν από καθεμία από τις τρεις ΝΜΒ1870 οικογένειες και εκφράζονται ως απλού πολυπεπτιδίου άλυσος. Οι εφευρέτες έχουν επίσης βρει ότι η ΝΜΒ1870 εκθέτει μερικούς από τους επίτοπους αυτής σε βρόχους επιφανείας τοποθετημένους μεταξύ άλφα ελίκων και ότι υποκατάσταση επίτοπων βρόχου από μία οικογένεια εντός της τοποθεσίας βρόχου σε άλλη οικογένεια επιτρέπει να παράγεται χιμαιρική ΝΜΒ1870 με πολυ-οικογένειας αντιγονικότητα. Παρέχονται αυτές οι χιμαιρικές ΝΜΒ1870 πρωτεΐνες, που περιλαμβάνουν τμήματα της ΝΜΒ1870 από διαφορετικές οικογένειες.
CY20131100064T 2004-09-01 2013-01-23 Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870 CY1113554T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0419408A GB0419408D0 (en) 2004-09-01 2004-09-01 741 chimeric polypeptides
EP20050786178 EP1784419B1 (en) 2004-09-01 2005-09-01 Domains and epitopes of meningococcal protein nmb1870

Publications (1)

Publication Number Publication Date
CY1113554T1 true CY1113554T1 (el) 2016-06-22

Family

ID=33155851

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100064T CY1113554T1 (el) 2004-09-01 2013-01-23 Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870

Country Status (20)

Country Link
US (1) US20090285845A1 (el)
EP (1) EP1784419B1 (el)
JP (2) JP4827196B2 (el)
CN (1) CN101031584B (el)
AU (1) AU2005278904B2 (el)
BR (1) BRPI0514829A (el)
CA (1) CA2578014A1 (el)
CY (1) CY1113554T1 (el)
DK (1) DK1784419T3 (el)
ES (1) ES2396422T3 (el)
GB (1) GB0419408D0 (el)
HR (1) HRP20130036T1 (el)
MX (1) MX2007002094A (el)
NZ (1) NZ553229A (el)
PL (1) PL1784419T3 (el)
PT (1) PT1784419E (el)
RS (1) RS52634B (el)
RU (1) RU2375374C2 (el)
SI (1) SI1784419T1 (el)
WO (1) WO2006024954A2 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
CA2838395C (en) * 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
DE60144353D1 (de) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE047780T2 (hu) * 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
RU2475496C2 (ru) * 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
CA2717870A1 (en) * 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CA2726512A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
NZ595291A (en) * 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2861247B1 (en) 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112016002150A2 (pt) 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EA038940B1 (ru) 2014-07-17 2021-11-12 Глаксосмитклайн Байолоджикалс С.А. Менингококковые вакцины
CA2954745A1 (en) 2014-07-17 2016-01-21 Glaxosmithkline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3298031B1 (en) 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
US20240016916A1 (en) 2020-05-15 2024-01-18 Biomvis S.R.L. Bacterial outer membrane vesicles carrying coronavirus polypeptides, method of preparation, compositions and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2238951C2 (ru) * 1998-03-31 2004-10-27 Тонгхуа Гэнтеч Биотекнолоджи Лтд. Химерный белок, обеспечивающий образование биоактивной конформации, способ получения белка с инсулиновой активностью, способ идентификации пептидильного фрагмента
NZ532665A (en) * 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
CA2838395C (en) * 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CN102172398A (zh) * 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
DE60144353D1 (de) * 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003260357B2 (en) * 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE047780T2 (hu) * 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
EP1961426B1 (en) * 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein

Also Published As

Publication number Publication date
RU2375374C2 (ru) 2009-12-10
HRP20130036T1 (hr) 2013-02-28
RS52634B (sr) 2013-06-28
SI1784419T1 (sl) 2013-02-28
RU2007111700A (ru) 2008-10-10
WO2006024954A3 (en) 2006-08-24
US20090285845A1 (en) 2009-11-19
NZ553229A (en) 2010-07-30
MX2007002094A (es) 2007-04-24
JP4827196B2 (ja) 2011-11-30
WO2006024954A9 (en) 2012-03-15
BRPI0514829A (pt) 2008-06-24
JP2011168611A (ja) 2011-09-01
CA2578014A1 (en) 2006-03-09
EP1784419A2 (en) 2007-05-16
WO2006024954A2 (en) 2006-03-09
ES2396422T3 (es) 2013-02-21
AU2005278904A1 (en) 2006-03-09
JP2008511306A (ja) 2008-04-17
DK1784419T3 (da) 2013-02-04
EP1784419B1 (en) 2012-10-24
CN101031584B (zh) 2012-09-05
PT1784419E (pt) 2013-01-15
GB0419408D0 (en) 2004-10-06
AU2005278904B2 (en) 2012-02-09
PL1784419T3 (pl) 2013-03-29
CN101031584A (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
CY1113554T1 (el) Πεδια και επιτοποι μηνιγγοκοκκικης πρωτεϊνης νμβ1870
CY1112342T1 (el) Χιμαιρικα, υβριδικα και διαδοχικα πολυπεπτιδια μηνιγγοκοκκικου νμβ1870
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NL300808I2 (nl) susoctocog alfa
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
UY28641A1 (es) Anticuerpos
BR0015961A (pt) Antìgeno de neisseria de 85kda
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119019T1 (el) Πολλαπλες παραλλαγες μηνιγγιοκοκκικης πρωτεϊνης νμβ 1870
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
DE60138927D1 (de) Menschlicher rezeptor für tumor necrosis factor
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
CY1108691T1 (el) Πολυπεπτιδια
DK1244705T3 (da) Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
IL172396A0 (en) Replikin peptides and uses thereof
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
DE602007006196D1 (de) Cysteingranulate und ihre verwendung als wachstumsstimulanzien für bifidobaceterium animalis lactis
UA87128C2 (ru) ИММУНОГЛОБУЛИН АНТИ-EрCAM И СПОСОБ ЕГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper